Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L29 pseudogene 1 (RPL29P1) is a processed pseudogene of the ribosomal protein L29 gene, meaning it is a non-functional genomic DNA sequence derived from the functional gene. It does not encode an active protein and has no known direct biological function or disease role. Pseudogenes like RPL29P1 arise from duplication or retrotransposition events of functional genes and are widespread in genomes, especially for ribosomal protein gene families. RPL29P1 is not a receptor, enzyme, transporter, or viable drug target and is not used as a biomarker. It should not be conflated with the functional ribosomal protein L29 (RPL29), which is a structural component of the 60S ribosomal subunit involved in protein synthesis[3][5][6].\n\nKey context:\n- RPL29P1 is listed in gene databases under pseudogenes and does not encode a functional protein[3][6].\n- Pseudogenes are non-coding; their roles (if any) are generally regulatory, but RPL29P1 itself is not known to have such a function[5].\n- There are no drugs, mechanisms of action, or safety concerns associated with RPL29P1.\n- Any therapeutic or functional information about "ribosomal protein L29" refers to the functional gene/product RPL29, not to RPL29P1.\n\nSummary: \nRPL29P1 is not a valid therapeutic target, but a processed pseudogene—essentially an inactive genomic relic without a direct functional or disease role[3][5][6]. Any information regarding ribosomal protein L29 function or disease links must refer to RPL29, the protein-coding gene, not its pseudogenes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L29 pseudogene 1 (RPL29P1).